We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Avacta | LSE:AVCT | London | Ordinary Share | GB00BYYW9G87 | ORD 10P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 2.50 | 5.71% | 46.25 | 1,820,700 | 16:22:56 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 45.50 | 47.00 | 47.50 | 43.75 | 43.75 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 23.25M | -24.95M | -0.0695 | -6.65 | 157.08M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 17:08:51 | O | 100,000 | 46.25 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 30/10/2024 | 07:00 | UK RNS | Avacta Group PLC R&D Spotlight focusing on pipeline advances |
| 28/10/2024 | 07:00 | UK RNS | Avacta Group PLC Block Listing Six Monthly Return |
| 24/10/2024 | 06:00 | UK RNS | Avacta Group PLC Avacta Reports Pipeline Avances at EORTC |
| 21/10/2024 | 15:00 | UK RNS | Avacta Group PLC Issue of Equity and Total Voting Rights |
| 21/10/2024 | 13:31 | ALNC |  Avacta partners with Tempus to enable AI-driven drug development |
| 21/10/2024 | 06:00 | UK RNS | Avacta Group PLC Avacta and Tempus Enter Strategic Collaboration |
| 17/10/2024 | 12:39 | ALNC | Avacta expands pipeline with two novel preclinical assets |
| 17/10/2024 | 06:00 | UK RNS | Avacta Group PLC Avacta Expands its Pipeline |
| 15/10/2024 | 10:18 | ALNC | EXECUTIVE CHANGES: PHSC co-founder and Deltic Energy CEO depart |
| 15/10/2024 | 06:00 | UK RNS | Avacta Group PLC Avacta appoints Chief Scientific Officer |
Avacta (AVCT) Share Charts1 Year Avacta Chart |
|
1 Month Avacta Chart |
Intraday Avacta Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 11/12/2024 | 21:50 | Avacta – Innovative and Disruptive Technologies for Global Health Markets | 58,828 |
| 25/6/2024 | 11:57 | Covid-19. Ten Minute Test. Gamechanger!! | 19,644 |
| 23/4/2024 | 12:44 | avct The Fall!!! | 141 |
| 23/4/2023 | 21:31 | Avacta – Unique and innovative technology blipping on big pharma’s radar | 1,851 |
| 23/2/2022 | 07:14 | CV And The Deep State | 228 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-12-11 17:08:51 | 46.25 | 100,000 | 46,250.00 | O |
| 2024-12-11 16:29:57 | 46.38 | 10,781 | 4,999.69 | O |
| 2024-12-11 16:26:13 | 46.38 | 8,163 | 3,785.59 | O |
| 2024-12-11 16:22:46 | 46.38 | 10,000 | 4,637.50 | O |
| 2024-12-11 16:19:38 | 45.79 | 4,395 | 2,012.34 | O |
| Top Posts |
|---|
Posted at 11/12/2024 08:20 by Avacta Daily Update Avacta is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker AVCT. The last closing price for Avacta was 43.75p.Avacta currently has 359,042,104 shares in issue. The market capitalisation of Avacta is £166,056,973. Avacta has a price to earnings ratio (PE ratio) of -6.65. This morning AVCT shares opened at 43.75p |
Posted at 21/11/2024 11:20 by m_night10 POLX FDA Approval received today big rise comingPOLX Polarean Imaging 1.6p I fancy to fill the gap to 3.2p and head to 10p+. Mcap is peanuts and cash position is much longer to Q2 2026 and revenue are higher and growing even more quickly than this.. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil in 2025 Cash runway to minimum of Q2 2026, looks set to be extended given revenues ahead of expectations. Putting this UK recovery play potential on radars as used to trade at 100p and has made significant commercial progress since FDA approval. Massive takeover target and will be sold for 20p+ share price. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target more massive premiums as per the above imv. DYOR, not advice. |
Posted at 20/11/2024 08:24 by m_night10 POLX Polarean Imaging 1.6p I fancy to fill the gap to 3.2p and head to 10p+. Mcap is peanuts 1/10th of AVCT and cash position is much longer to Q2 2026 and revenue are higher and growing even more quickly than this.. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil in 2025 Cash runway to minimum of Q2 2026, looks set to be extended given revenues ahead of expectations.Putting this UK recovery play potential on radars as used to trade at 100p and has made significant commercial progress since FDA approval. Massive takeover target and will be sold for 20p+ share price. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target more massive premiums as per the above imv. DYOR, not advice. |
Posted at 13/11/2024 08:33 by m_night10 POLX Polarean Imaging about to break out above 2p soon. Mcap is peanuts and cash position is much longer to Q2 2026 and revenue are higher and growing even more quickly than this.. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil. 1.55p and gap at over 3p. ATH 100p. Cash runway to minimum of Q2 2026, looks set to be extended given revenues ahead of expectations.Putting this UK recovery play potential on radars. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target more massive premiums as per the above imv. DYOR, not advice. |
Posted at 12/11/2024 07:50 by m_night10 POLX Polarean Imaging will break out above 2p soon. Mcap only $20mil. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil. 1.55p and gap at over 3p. ATH 100p. Cash runway to minimum of Q1 2026, looks set to be extended given revenues ahead of expectations.Putting this UK recovery play potential on radars. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target imv. DYOR, not advice. |
Posted at 08/11/2024 07:32 by m_night10 POLX Polarean Imaging about to break out above 2p soon. Mcap only $25mil. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil. 1.65p and gap at over 3p. ATH 100p. Cash runway to minimum of Q1 2026, looks set to be extended given revenues ahead of expectations.Putting this UK recovery play potential on radars. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target imv. DYOR, not advice. |
Posted at 22/10/2024 07:47 by pwhite73 However I reiterate the company is now on the right path if it wants to raise the share price. Going back to square one with new pre-clinical drugs that use preCISION and rope in the dead horse Affimers is the only way to boost the share price.At this early stage they can talk about partnerships with AI companies without having to prove damn thing. |
Posted at 12/9/2024 18:09 by waldron THE AVCT SHARE PRICEAnd when they were up they were up, And when they were down they were down, And when they were only half way up They were neither up nor down. RESULTS SHOULD SOON CLARIFY share price DIRECTION GOOD LUCK ALL |
Posted at 15/7/2024 08:25 by jaknife Rajraj b,”Should be an interesting week for the share price. We are due some news updates. Let’s see what happens” The only scheduled news update is the quarterly conversion that’s due under the death spiral. In order to maximise their profits from the conversion the market maker that is ultimately the owner of the death spiral needs to: A. Sell shares in the market at the highest price possible, eg by moving the price up (giving the illusion of momentum), which encourages punters to pile in and buy (from the market maker who goes short). B. Buy shares at the lowest price possible, eg by crashing the share price in the run up to the conversion date thus making the VWAP formula for the death spiral produce a low price. Who thinks that the market maker will try to maximise their profit? And hands up who thinks that the market maker is a friendly kind soul who exists to help you make a profit? JakNife |
Posted at 04/7/2024 10:35 by jaknife PWhite73,"The rise in the share price reflects a more credible management team and a more effective PR campaign." The rise in the share price simply reflects the market maker moving the share price up. People assume that buying activity has moved the share price up but that's not necessarily how markets work. The easiest way to encourage buying activity is to create the illusion of momentum first! There's a conversion due on the death spiral in just over two weeks time and hence the market maker needs to sell something like 5m shares between now and then. JakNife |
Posted at 03/6/2024 09:25 by pwhite73 Rajraj b - Yes I still do. AVCT has just raised £28 million. It is my opinion they are not going to waste anymore money on the never ending AVA6000 Phase 1 trials. AVCT needs to boost the share price or they can't meet their loan obligations without totally destroying what's left of shareholder value.AVCT and SOFIE are both looking at the use of FAP to kill cancer cells. AVCT as a means of recognition and SOFIE as a means of inhibition. RNS 28/03/24 - "This sub-study represents an ongoing collaboration between Avacta and SOFIE, in the use of [18F]FAPI-74 PET as a complementary diagnostic. [18F]FAPI-74 PET is currently in clinical development and for investigational use only." So we know they have been working together prior to the date of the RNS. A full joint venture to kill cancer cells will perhaps give AVCT the boost they so desperately need. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
